 While large-cap biotech companies have been doing quite well, investors can frequently find market-beating performance in emerging biotechs developing cutting-edge treatments. First up is Ovid Therapeutics NASDAQ: OVID, with a 365 million market cap This company is developing a treatment for Angelman syndrome, a genetic disease causing profound developmental delay in children. The treatment, called OV101, is designed to mitigate excessive neurotransmission between neurons that is thought to contribute to Angelman syndrome. 